<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36443">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632110</url>
  </required_header>
  <id_info>
    <org_study_id>CP0112</org_study_id>
    <nct_id>NCT02632110</nct_id>
  </id_info>
  <brief_title>Microneedle Lesion Preparation Prior to ALA-PDT for AK on Face</brief_title>
  <official_title>A Phase 2 Study of the Effect of Microneedle Lesion Preparation, Incubation Time and Light Power Density on Photodynamic Therapy With Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% + Blue Light for the Field Treatment of Actinic Keratoses on the Face</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DUSA Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DUSA Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the viability of microneedle lesion preparation
      (MN) to enhance treatment benefit when performed prior to ALA PDT to an actinic keratosis
      (AK) field on the face.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">September 12, 2016</completion_date>
  <primary_completion_date type="Actual">September 12, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Clearance Rate</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of subjects in each treatment group with a count of zero lesions in the AK Field</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Clearance Rate</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction Score</measure>
    <time_frame>Week 12</time_frame>
    <description>Subject satisfaction score
= Excellent (very satisfied)
= Good (moderately satisfied)
= Fair (slightly satisfied)
= Poor (not satisfied at all)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline AKCR</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>AK clearance rate for only those lesions present at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline AKCR</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>AK clearance rate for only those lesions present at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Percent change in the total AK number as compared with Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percent change in the total AK number as compared with Baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hyperpigmentation</measure>
    <time_frame>Baseline</time_frame>
    <description>HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyperpigmentation</measure>
    <time_frame>24-48 hours after PDT #1</time_frame>
    <description>HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyperpigmentation</measure>
    <time_frame>2 Weeks after PDT #1</time_frame>
    <description>HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyperpigmentation</measure>
    <time_frame>8 Weeks after PDT #1</time_frame>
    <description>HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyperpigmentation</measure>
    <time_frame>12 Weeks after PDT #1</time_frame>
    <description>HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypopigmentation</measure>
    <time_frame>Baseline</time_frame>
    <description>HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypopigmentation</measure>
    <time_frame>24-48 hours after PDT #1</time_frame>
    <description>HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypopigmentation</measure>
    <time_frame>2 Weeks after PDT #1</time_frame>
    <description>HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypopigmentation</measure>
    <time_frame>4 Weeks after PDT #1</time_frame>
    <description>HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypopigmentation</measure>
    <time_frame>8 Weeks after PDT #1</time_frame>
    <description>HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypopigmentation</measure>
    <time_frame>12 Weeks after PDT #1</time_frame>
    <description>HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation</description>
  </other_outcome>
  <other_outcome>
    <measure>Erythema</measure>
    <time_frame>Baseline</time_frame>
    <description>Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema</description>
  </other_outcome>
  <other_outcome>
    <measure>Erythema</measure>
    <time_frame>5 minutes after PDT #1</time_frame>
    <description>Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema</description>
  </other_outcome>
  <other_outcome>
    <measure>Erythema</measure>
    <time_frame>24-48 hours after PDT #1</time_frame>
    <description>Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema</description>
  </other_outcome>
  <other_outcome>
    <measure>Erythema</measure>
    <time_frame>2 Weeks after PDT #1</time_frame>
    <description>Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema</description>
  </other_outcome>
  <other_outcome>
    <measure>Erythema</measure>
    <time_frame>8 Weeks after PDT #1</time_frame>
    <description>Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema</description>
  </other_outcome>
  <other_outcome>
    <measure>Erythema</measure>
    <time_frame>12 Weeks after PDT #1</time_frame>
    <description>Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema</description>
  </other_outcome>
  <other_outcome>
    <measure>Edema</measure>
    <time_frame>Baseline</time_frame>
    <description>﻿EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area</description>
  </other_outcome>
  <other_outcome>
    <measure>Edema</measure>
    <time_frame>5 minutes after PDT #1</time_frame>
    <description>﻿EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area</description>
  </other_outcome>
  <other_outcome>
    <measure>Edema</measure>
    <time_frame>24-48 hours after PDT #1</time_frame>
    <description>﻿EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area</description>
  </other_outcome>
  <other_outcome>
    <measure>Edema</measure>
    <time_frame>2 weeks after PDT #1</time_frame>
    <description>﻿EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area</description>
  </other_outcome>
  <other_outcome>
    <measure>Edema</measure>
    <time_frame>4 Weeks after PDT #1</time_frame>
    <description>﻿EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area</description>
  </other_outcome>
  <other_outcome>
    <measure>Edema</measure>
    <time_frame>8 Weeks after PDT #1</time_frame>
    <description>﻿EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area</description>
  </other_outcome>
  <other_outcome>
    <measure>Edema</measure>
    <time_frame>12 Weeks after PDT #1</time_frame>
    <description>﻿EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area</description>
  </other_outcome>
  <other_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>Baseline</time_frame>
    <description>﻿STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable</description>
  </other_outcome>
  <other_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>During PDT #1</time_frame>
    <description>﻿Immediately after PDT, the most intensive, acute perception of Stinging/Burning DURING treatment will be recorded.
STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable</description>
  </other_outcome>
  <other_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>5 minutes after PDT #1</time_frame>
    <description>﻿STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable</description>
  </other_outcome>
  <other_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>2 Weeks after PDT #1</time_frame>
    <description>﻿STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable</description>
  </other_outcome>
  <other_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>4 Weeks after PDT #1</time_frame>
    <description>﻿STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable</description>
  </other_outcome>
  <other_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>8 Weeks after PDT #1</time_frame>
    <description>﻿STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable</description>
  </other_outcome>
  <other_outcome>
    <measure>Stinging/Burning</measure>
    <time_frame>12 Weeks after PDT #1</time_frame>
    <description>﻿STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable</description>
  </other_outcome>
  <other_outcome>
    <measure>Scaling &amp; Dryness</measure>
    <time_frame>Baseline</time_frame>
    <description>﻿SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling</description>
  </other_outcome>
  <other_outcome>
    <measure>Scaling &amp; Dryness</measure>
    <time_frame>24-48 hours after PDT #1</time_frame>
    <description>﻿SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling</description>
  </other_outcome>
  <other_outcome>
    <measure>Scaling &amp; Dryness</measure>
    <time_frame>2 Weeks after PDT #1</time_frame>
    <description>﻿SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling</description>
  </other_outcome>
  <other_outcome>
    <measure>Scaling &amp; Dryness</measure>
    <time_frame>8 Weeks after PDT #1</time_frame>
    <description>﻿SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling</description>
  </other_outcome>
  <other_outcome>
    <measure>Scaling &amp; Dryness</measure>
    <time_frame>12 Weeks after PDT #1</time_frame>
    <description>﻿SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling</description>
  </other_outcome>
  <other_outcome>
    <measure>Oozing/Vesiculation/Crusting</measure>
    <time_frame>Baseline</time_frame>
    <description>OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above</description>
  </other_outcome>
  <other_outcome>
    <measure>Oozing/Vesiculation/Crusting</measure>
    <time_frame>24-48 hours after PDT #1</time_frame>
    <description>OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above</description>
  </other_outcome>
  <other_outcome>
    <measure>Oozing/Vesiculation/Crusting</measure>
    <time_frame>2 Weeks after PDT #1</time_frame>
    <description>OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above</description>
  </other_outcome>
  <other_outcome>
    <measure>Oozing/Vesiculation/Crusting</measure>
    <time_frame>8 Weeks after PDT #1</time_frame>
    <description>OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above</description>
  </other_outcome>
  <other_outcome>
    <measure>Oozing/Vesiculation/Crusting</measure>
    <time_frame>12 Weeks after PDT #1</time_frame>
    <description>OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above</description>
  </other_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>ALA 25 min 10 mW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MN + ALA 25 min 10 mW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA 25 min 20 mW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MN + ALA 25 min 20 mW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA 60 min 10 mW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MN + ALA 60 min 10mW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA 60 min 20 mW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MN + ALA 60 min 20 mW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VEH</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MN + VEH</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microneedle lesion preparation prior to Vehicle PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALA</intervention_name>
    <description>20% ALA applied to face prior to light treatment</description>
    <arm_group_label>ALA 25 min 10 mW</arm_group_label>
    <arm_group_label>MN + ALA 25 min 10 mW</arm_group_label>
    <arm_group_label>ALA 25 min 20 mW</arm_group_label>
    <arm_group_label>MN + ALA 25 min 20 mW</arm_group_label>
    <arm_group_label>ALA 60 min 10 mW</arm_group_label>
    <arm_group_label>MN + ALA 60 min 10mW</arm_group_label>
    <arm_group_label>ALA 60 min 20 mW</arm_group_label>
    <arm_group_label>MN + ALA 60 min 20 mW</arm_group_label>
    <other_name>Levulan Kerastick</other_name>
    <other_name>Aminolevulinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Solution Vehicle</intervention_name>
    <description>Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face prior to light treatment</description>
    <arm_group_label>VEH</arm_group_label>
    <arm_group_label>MN + VEH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IBL 10 mW</intervention_name>
    <description>10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds</description>
    <arm_group_label>ALA 25 min 10 mW</arm_group_label>
    <arm_group_label>MN + ALA 25 min 10 mW</arm_group_label>
    <arm_group_label>ALA 60 min 10 mW</arm_group_label>
    <arm_group_label>MN + ALA 60 min 10mW</arm_group_label>
    <arm_group_label>VEH</arm_group_label>
    <arm_group_label>MN + VEH</arm_group_label>
    <other_name>Investigational Blue Light</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microneedle lesion preparation</intervention_name>
    <description>Microneedling of all visible/palpable AK lesions prior to solution application.</description>
    <arm_group_label>MN + ALA 25 min 10 mW</arm_group_label>
    <arm_group_label>MN + ALA 25 min 20 mW</arm_group_label>
    <arm_group_label>MN + ALA 60 min 10mW</arm_group_label>
    <arm_group_label>MN + ALA 60 min 20 mW</arm_group_label>
    <arm_group_label>MN + VEH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IBL 20 mW</intervention_name>
    <description>10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds</description>
    <arm_group_label>ALA 25 min 20 mW</arm_group_label>
    <arm_group_label>MN + ALA 25 min 20 mW</arm_group_label>
    <arm_group_label>ALA 60 min 20 mW</arm_group_label>
    <arm_group_label>MN + ALA 60 min 20 mW</arm_group_label>
    <other_name>Investigational Blue Light</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Four to eight AKs on the face

        Exclusion Criteria:

          -  Pregnancy

          -  history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or
             photodermatosis

          -  lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated
             skin cancers within the Treatment Area

          -  skin pathology or condition which could interfere with the evaluation of the test
             product or requires the use of interfering topical or systemic therapy

          -  Subject is immunosuppressed

          -  currently enrolled in an investigational drug or device study

          -  has received an investigational drug or been treated with an investigational device
             within 30 days prior to the initiation of treatment

          -  known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl
             alcohol, laureth 4, polyethylene glycol)

          -  has an active herpes simplex infection OR a history of 2 or more outbreaks within the
             past 12 months, on the face

          -  use of the following topical preparations on the extremity to be treated:

               -  Keratolytics including urea (greater than 5%), alpha hydroxyacids [e.g.glycolic
                  acid, lactic acid, etc. greater than 5%], salicylic acid (greater than 2%)
                  within 2 days

               -  Curettage or Cryotherapy within 2 weeks of initiation of treatment

               -  Retinoids, including tazarotene, adapalene, tretinoin, within 4 weeks

               -  Microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-FU,
                  diclofenac, ingenol mebutate, imiquimod or other topical treatments for AK
                  within 8 weeks

          -  use of systemic retinoid therapy within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Marcus, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>DUSA Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MOORE Clinical Research, Inc</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altman Dermatology Associates</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shideler Clinical Research Center</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center, PC</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>December 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
